Abaloparatide vs. Placebo in Postmenopausal Women Receiving Initial Spinal Fusion Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03841058|
Recruitment Status : Not yet recruiting
First Posted : February 15, 2019
Last Update Posted : February 15, 2019
|Condition or disease||Intervention/treatment||Phase|
|Spinal Fusion||Drug: Abaloparatide Drug: Placebo||Phase 2|
This is a prospective randomized, double-blinded, placebo-controlled, phase 2, 12-month pilot to study the efficacy of abaloparatide in postmenopausal women needing lumbar spinal fusion surgery. Seventy-two women with low bone mass who are scheduled to undergo spinal fusion surgery will be randomized 2:1 in a blinded fashion to receive either 80 mcg of abaloparatide subcutaneously (SC) every day or an identical-appearing placebo SC for 6 months. This study has 3 objectives:
- In this pilot study the investigators will evaluate surgical outcomes at one year (enhanced bone union, reduced pedicle screw loosening, adjacent segment fracture and proximal junctional kyphosis) and compare the impact of 6 months of abaloparatide vs. placebo on surgical success, these data will be used to determine effect sizes and variance to power the next larger clinical trial.
- To determine if abaloparatide/Tymlos versus placebo leads to a faster reduction in pain as assessed by both the Numeric Rating Scale (NRS) and the Oswestry Disability Index for low back pain at 6 months.
- As an exploratory proof of concept objective the investigators will determine if abaloparatide/Tymlos versus placebo results in greater fusion bone mass volume (FBMV) as a marker of bone union at 6 months and 1 year to see whether at one year post lumbar spinal fusion surgery, greater FBMV is associated with improved spinal surgery outcomes including: enhanced bone union, reduced pedicle screw loosening, adjacent segment fracture and proximal junctional kyphosis. This would serve as evidence that FBMV can be used as an early validated marker of fusion surgery success.
All analyses will be two-sided and the alpha level will be set at 0.05. FBMV, pain and function will be compared by drug (Abaloparatide vs. placebo) at 6 months. The investigators will evaluate FBMV as a continuous variable and evaluate differences in this outcome between abaloparatide and placebo groups at 6 months as an exploratory outcome variable. The investigators will evaluate bone union and reduced pedicle screw loosening, adjacent segment fracture, and proximal junctional kyphosis as dichotomous variables at 12 months using logistic regression and determine if FBMV differs in those exhibiting each of these outcomes for validity of FBMV, regardless of prior treatment group. In addition, these data will be used to determine effect sizes and variance to power the next larger clinical trial. The investigators will evaluate NRS and ODI score by using repeated measures of these variables over time by treatment group and evaluate NRS at 6 months in the placebo versus abaloparatide group. Comorbidity, age, prior fracture, prior use of bisphosphonates and other covariates will be evaluated, via multivariable regression, as to whether they lead to a change in the estimate of effect in order to be considered for inclusion in the models.
If abaloparatide can improve outcomes following lumbar spine fusion surgery, this pilot study could lead to the requisite two year trial that may have an impact on the treatment of fusion surgery patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized controlled trial|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Placebo will be used that will be identical to active drug in appearance|
|Official Title:||Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery|
|Estimated Study Start Date :||May 2019|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2021|
Active Comparator: Abaloparatide
Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
80 mcg delivered SC by a pen
Other Name: Tymlos
Placebo Comparator: Placebo
Placebo administered subcutaneously with a pen once daily for 6 months
A pen to deliver a SC dose of placebo
Other Name: placebo pen
- Difference in measure of fusion mass bridging from transverse process to transverse process [ Time Frame: one year ]CT assessment of fusion mass using a qualitative five-point scale to assess fusion quality (1 = unfused, 2 = partial unilateral fusion, 3 = partial bilateral fusion, 4 = complete unilateral fusion, 5 = complete bilateral fusion)
- Difference in incidence of adverse surgical outcomes [ Time Frame: one year ]Adverse outcomes include pedicle screw loosening, adjacent segment fracture and proximal junctional kyphosis will be evaluated on CT images
- Pain assessed by the Numeric Rating Scale [ Time Frame: 6 months ]Numeric Rating Scale (NRS) from 0 to 10 with higher scores indicating more pain.
- Pain assessed by the Oswestry Disability Index [ Time Frame: 6 months ]Oswestry Disability Index for low back pain with a score of 0 to 50 points or 0 to 100%. Higher scores indicate more pain.
- CT evaluation of Fusion bone mass volume [ Time Frame: 6 months and 1 year ]fusion bone mass volume (FBMV) as a marker of bone union will be assessed on CT images